Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radioimmunotherapy for acute leukemia.

John M Burke1, Joseph G Jurcic, David A Scheinberg

  • 1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. burkej@mskcc.org

Cancer Control : Journal of the Moffitt Cancer Center
|April 20, 2002
PubMed
Summary

Radioimmunotherapy using radiolabeled antibodies shows promise for leukemia treatment, delivering targeted radiation to cancer cells. Further randomized studies are needed to confirm improved patient outcomes in leukemia therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Future oncology (London, England)·2026
Same author

Consolidation of Oncology Practices.

JCO oncology practice·2026
Same author

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

Lancet (London, England)·2026
Same author

T-Cell Clonal Expansion in Peripheral Blood Following Interventional Radiology Procedures for Metastatic Liver Cancer.

Cancers·2026
Same author

Targeted cellular micropharmacies deliver therapeutic agents to the brain.

EMBO molecular medicine·2026
Same author

Treatment-emergent coagulopathy during azacitidine/venetoclax induction in AML.

Blood neoplasia·2026

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Immunotherapy

Background:

  • Monoclonal antibodies are being utilized to deliver radioactive isotopes directly to tumor cells.
  • This strategy aims to enhance the antitumor effects of native monoclonal antibodies.
  • Radioimmunotherapy is a key therapeutic strategy in leukemia treatment.

Purpose of the Study:

  • To summarize the role of radioimmunotherapy in treating leukemia.
  • To review published clinical trials of radioimmunotherapy in acute leukemia.

Main Methods:

  • Review of published clinical trials.
  • Analysis of radioimmunotherapy applications in acute leukemia.

Main Results:

  • Beta-particle emitting radioimmunoconjugates (e.g., 131I-anti-CD33, 90Y-anti-CD33) deliver significant radiation doses to bone marrow, potentially aiding hematopoietic stem cell transplantation conditioning.

Related Experiment Videos

  • Alpha-particle emitting radioimmunoconjugates (e.g., 213Bi-anti-CD33) are suitable for treating low-volume or residual leukemia.
  • Radiolabeled antibodies can be safely administered to advanced leukemia patients, demonstrating significant antileukemic activity.

    • Conclusions:

    • Radiolabeled antibodies offer a safe and effective treatment option for advanced leukemias.
    • They can potentially enhance conditioning regimens in hematopoietic stem cell transplantation.
    • Randomized studies are required to definitively establish improved outcomes for leukemia patients treated with radiolabeled antibodies.